iso-butyl 4-methyl-2-oxopentanoate

• 分子结构分类: 有机化合物 - 脂质和类脂质分子 - 脂肪酰基
• 英文名称: iso-butyl 4-methyl-2-oxopentanoate
• 英文别名: 2-methylpropyl 4-methyl-2-oxopentanoate
• 化学式: C₁₀H₁₈O₃
• 分子量: 186.251
• InChiKey: ZHYGNSQJTOTYOZ-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  2.6
• 重原子数：
  13
• 可旋转键数：
  6
• 环数：
  0.0
• sp3杂化的碳原子比例：
  0.8
• 拓扑面积：
  43.4
• 氢给体数：
  0
• 氢受体数：
  3

反应信息

• 作为反应物：
  描述：

  iso-butyl 4-methyl-2-oxopentanoate 在 三乙烯二胺 、 1-[3,5-双(三氟甲基)苯基]-3-[(1R,2R)-(-)-2-(二甲氨基)环己基]硫脲 作用下， 以 乙酸乙酯 为溶剂， 反应 96.0h， 生成 isobutyl (4S,5S)-3-isopropyl-4-(4-methoxyphenyl)-5-nitro-4,5-dihydrofuran-2-carboxylate
  参考文献：
  名称：

  由α-酮酯和（Z）-β-氯-β-硝基苯乙烯对映体选择性催化连续合成4,5-二氢呋喃-2-羧酸烷基酯

  摘要：

  献给教授迪特尔·恩德斯在他70之际个生日 抽象的 通过α-酮酸酯和（Z）-（2-氯-2-硝基乙烯基）苯之间的对映选择性有机催化连续反应，可以有效地获得4，5-二氢呋喃-2-羧酸烷基酯。整个序列结合了（R，R）-TUC催化的迈克尔加成与DABCO促进的分子内O-烷基化，得到标题产物，为单一非对映异构体，对映体过量从86％到97％。 通过α-酮酸酯和（Z）-（2-氯-2-硝基乙烯基）苯之间的对映选择性有机催化连续反应，可以有效地获得4，5-二氢呋喃-2-羧酸烷基酯。整个序列结合了（R，R）-TUC催化的迈克尔加成与DABCO促进的分子内O-烷基化，得到标题产物，为单一非对映异构体，对映体过量从86％到97％。

  DOI：

  10.1055/s-0035-1562446
• 作为产物：
  描述：

  4-甲基-2-氧代戊酸 、 异丁醇 在 吡啶 、 甲基磺酰氯 作用下， 以 四氢呋喃 为溶剂， 以83%的产率得到iso-butyl 4-methyl-2-oxopentanoate
  参考文献：
  名称：

  由α-酮酯和（Z）-β-氯-β-硝基苯乙烯对映体选择性催化连续合成4,5-二氢呋喃-2-羧酸烷基酯

  摘要：

  献给教授迪特尔·恩德斯在他70之际个生日 抽象的 通过α-酮酸酯和（Z）-（2-氯-2-硝基乙烯基）苯之间的对映选择性有机催化连续反应，可以有效地获得4，5-二氢呋喃-2-羧酸烷基酯。整个序列结合了（R，R）-TUC催化的迈克尔加成与DABCO促进的分子内O-烷基化，得到标题产物，为单一非对映异构体，对映体过量从86％到97％。 通过α-酮酸酯和（Z）-（2-氯-2-硝基乙烯基）苯之间的对映选择性有机催化连续反应，可以有效地获得4，5-二氢呋喃-2-羧酸烷基酯。整个序列结合了（R，R）-TUC催化的迈克尔加成与DABCO促进的分子内O-烷基化，得到标题产物，为单一非对映异构体，对映体过量从86％到97％。

  DOI：

  10.1055/s-0035-1562446

文献信息

• Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20020045747A1

  公开（公告）日：2002-04-18

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  公开了抑制β-淀粉样肽释放和/或其合成的化合物，因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这些药物组合物预防性和治疗性治疗阿尔茨海默病的方法。
• Heterocyclic compounds, pharmaceutical compositions comprising same, and methods for inhibiting &bgr;-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：Athena Neurosciences, Inc.

  公开号：US06506782B1

  公开（公告）日：2003-01-14

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  公开了抑制β-淀粉样肽释放和/或其合成的化合物，因此可用于治疗阿尔茨海默病。还公开了包含抑制β-淀粉样肽释放和/或其合成的化合物的药物组合物，以及使用这些药物组合物预防性和治疗性地治疗阿尔茨海默病的方法。
• N-(aryl/heteroaryl) amino acid esters, pharmaceutical compositions
  申请人：Athena Neurosciences, Inc.

  公开号：US05965614A1

  公开（公告）日：1999-10-12

  Disclosed are compounds which inhibit .beta.-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits .beta.-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  揭示了一种抑制β-淀粉样肽释放和/或合成的化合物，因此，对治疗阿尔茨海默病具有实用价值。还揭示了包括抑制β-淀粉样肽释放和/或合成的化合物的药物组合物，以及使用这种药物组合物预防性和治疗性治疗阿尔茨海默病的方法。
• Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting B-amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20020173504A1

  公开（公告）日：2002-11-21

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  本发明涉及抑制&bgr;-淀粉样肽的释放和/或合成的化合物，因此具有治疗阿尔茨海默病的效用。还公开了包含抑制&bgr;-淀粉样肽释放和/或合成的化合物的药物组合物，以及使用这种药物组合物预防和治疗阿尔茨海默病的方法。
• Cycloalkyl, lactam, lactone and related compounds, pharmaceutical compositions comprising same, and methods for inhibiting beta-Amyloid peptide release and/or its synthesis by use of such compounds
  申请人：——

  公开号：US20020111343A1

  公开（公告）日：2002-08-15

  Disclosed are compounds which inhibit &bgr;-amyloid peptide release and/or its synthesis, and, accordingly, have utility in treating Alzheimer's disease. Also disclosed are pharmaceutical compositions comprising a compound which inhibits &bgr;-amyloid peptide release and/or its synthesis as well as methods for treating Alzheimer's disease both prophylactically and therapeutically with such pharmaceutical compositions.

  本发明涉及一种抑制β-淀粉样肽释放和/或合成的化合物，因此具有治疗阿尔茨海默病的效用。本发明还涉及包含抑制β-淀粉样肽释放和/或合成的化合物的制药组合物，以及使用这种制药组合物预防和治疗阿尔茨海默病的方法。